GSK plc (LON:GSK) Receives Average Rating of “Hold” from Brokerages

Shares of GSK plc (LON:GSK) have been given an average rating of “Hold” by the seven ratings firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is GBX 1,917.86.

GSK has been the subject of several analyst reports. Shore Capital Group reiterated a “buy” rating and set a GBX 2,300 price objective on shares of GSK in a research report on Wednesday, February 4th. JPMorgan Chase & Co. reissued an “underweight” rating on shares of GSK in a report on Wednesday, January 7th. Jefferies Financial Group restated a “buy” rating and set a GBX 2,100 price objective on shares of GSK in a research note on Wednesday, January 7th. Citigroup increased their target price on shares of GSK from GBX 1,900 to GBX 2,250 and gave the company a “buy” rating in a research report on Monday, February 9th. Finally, Deutsche Bank Aktiengesellschaft raised their target price on shares of GSK from GBX 1,600 to GBX 1,675 and gave the company a “hold” rating in a research note on Thursday, January 15th.

GSK Trading Down 0.3%

Shares of LON:GSK opened at GBX 1,965.77 on Friday. The company has a quick ratio of 0.73, a current ratio of 0.82 and a debt-to-equity ratio of 108.20. The company’s 50-day moving average price is GBX 2,022.60 and its 200 day moving average price is GBX 1,807.70. The company has a market cap of £78.85 billion, a PE ratio of 14.16, a P/E/G ratio of 1.24 and a beta of 0.32. GSK has a fifty-two week low of GBX 1,242.50 and a fifty-two week high of GBX 2,282.

GSK (LON:GSK) last posted its earnings results on Wednesday, February 4th. The company reported GBX 172 EPS for the quarter. GSK had a net margin of 17.50% and a return on equity of 37.19%. Sell-side analysts anticipate that GSK will post 175.980975 earnings per share for the current year.

Insider Activity

In other news, insider Jonathan Symonds acquired 2,500 shares of the business’s stock in a transaction dated Thursday, February 5th. The stock was acquired at an average price of GBX 2,114 per share, for a total transaction of £52,850. Also, insider Luke Miels sold 15,579 shares of the firm’s stock in a transaction dated Friday, February 13th. The shares were sold at an average price of GBX 2,160, for a total value of £336,506.40. In the last ninety days, insiders have bought 7,931 shares of company stock worth $16,480,489. 0.26% of the stock is owned by company insiders.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.